The Tumor Microbiome–Microenvironment Nexus: Unraveling Therapeutic Horizons 

Description

Emerging evidence has shed light on the complexity of the gut microbiome and its influence on the tumor immune microenvironment, tumorigenesis, and therapeutic responses. Sequencing studies have examined the differential microbiota composition between healthy individuals and patients with cirrhotic liver disease. Recent studies have shown the influence of the gut microbiome on liver cancer development and progression. Thereby, the gut microbiome represents a potential target for therapeutic intervention, and its composition may potentially serve as a predictive biomarker for enhanced responses to immunotherapy. In this session, experts review recent advances in our understanding of: (1) the role of the gut microbiome in influencing liver cancer tumorigenesis and progression; (2) the effect of the gut microbiome on immunotherapy sensitivities; (3) the relationship of the gut microbiome with the immune system; and (4) the development of novel therapeutics.